title: Angiogenic factors and acute-phase proteins in serum samples of preeclampsia and HELLP patients: a matched-pair analysis.
abstract: OBJECTIVE
  To investigate the serum level distribution of angiogenic markers (PlGF, endoglin, sFlt-1) and acute-phase proteins (SAA, CRP) in patients with HELLP syndrome or preeclampsia (PE) including matched controls.
  
  
  METHODS
  The matching procedure revealed 46 controls for 23 HELLP cases, and 81 controls for 42 preeclamptic patients. Maternal serum concentrations were determined by immunoassays.
  
  
  RESULTS
  SAA and CRP levels were significantly higher in HELLP patients compared with controls. This finding was not observed in preeclamptic subgroup. Pro-angiogenic PlGF is significantly lower in PE and HELLP syndrome. Anti-angiogenic endoglin is significantly higher in PE and HELLP syndrome. The sFlt-1 analysis supports the anti-angiogenic shift in HELLP and preeclamptic patients, but with smaller differences between subgroups. The SAA/PlGF ratio showed the highest ROC value of all tested parameters in discrimination between HELLP and HELLP controls.
  
  
  CONCLUSIONS
  These findings support the concept that patients with HELLP syndrome have both an anti-angiogenic state and a pronounced inflammatory response, while patients with PE are characterized only by an anti-angiogenic shift.
authors.affiliation: University of Rostock, Department of Obstetrics and Gynecology, Rostock, Germany. toralf.reimer@med.uni-rostock.de
authors.forename: Toralf
authors.initials: T
authors.lastname: Reimer
authors.forename: Henrike
authors.initials: H
authors.lastname: Rohrmann
authors.forename: Johannes
authors.initials: J
authors.lastname: Stubert
authors.forename: Ulrich
authors.initials: U
authors.lastname: Pecks
authors.forename: Michael O
authors.initials: MO
authors.lastname: Glocker
authors.forename: Dagmar-Ulrike
authors.initials: DU
authors.lastname: Richter
authors.forename: Bernd
authors.initials: B
authors.lastname: Gerber
mesh_terms: D000209:Acute-Phase Proteins / Q000032:analysis*; D000328:Adult; D043925:Angiogenesis Inducing Agents / Q000097:blood*; D015703:Antigens, CD / Q000032:analysis / Q000097:blood; D002097:C-Reactive Protein / Q000032:analysis; D016022:Case-Control Studies; D000071063:Endoglin; D005260:Female; D017359:HELLP Syndrome / Q000097:blood*; D006801:Humans; D007231:Infant, Newborn; D016555:Matched-Pair Analysis; D000072483:Placenta Growth Factor; D011225:Pre-Eclampsia / Q000097:blood*; D011247:Pregnancy; D011257:Pregnancy Proteins / Q000032:analysis / Q000097:blood; D011956:Receptors, Cell Surface / Q000032:analysis / Q000097:blood; D055815:Young Adult
chemical_list: D000209:Acute-Phase Proteins; D043925:Angiogenesis Inducing Agents; D015703:Antigens, CD; C064206:ENG protein, human; D000071063:Endoglin; C000608036:PGF protein, human; D011257:Pregnancy Proteins; D011956:Receptors, Cell Surface; D000072483:Placenta Growth Factor; D002097:C-Reactive Protein